ArticleAmerican journal of translational research2025
Ginsenoside Rg3 exerts anticancer effects in lung cancer through metabolite Histon H3.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the effects of ginsenoside Rg3 on metabolites in lung cancer cells.
methodsA549 cells were inoculated into nude BALB/c mice. Ginsenoside Rg3 (0.2 mL) or normal saline was orally administered daily for 12 days. LC/MS-based metabolomics was performed to analyze the metabolite profiles across three groups.
resultsIn serum samples, 143 metabolites were significantly different between the model and ginsenoside Rg3 groups. In fecal samples, 44 metabolites differed significantly between the two groups. Levels of Lamin A/C and Histon H3 were upregulated in model tissues. Ginsenoside Rg3 treatment significantly inhibited the expression of Lamin A/C and Histon H3, suggesting inhibition of histidine metabolism activation in lung cancer. Furthermore, ginsenoside Rg3 or Lamin A knockdown inhibited histamine-induced proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) in lung cancer cells.
conclusionsGinsenoside Rg3 significantly altered the metabolic profile in lung cancer mice. Mechanistically, ginsenoside Rg3 downregulated Lamin A/C through histidine metabolic pathway and suppressed histamine-induced progression of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.